CNBX - Cannabics Pharmaceuticals Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.652
-0.018 (-2.69%)
At close: 3:49PM EDT
Stock chart is not supported by your current browser
Previous Close0.670
Open0.658
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.650 - 0.665
52 Week Range0.600 - 2.990
Volume317,034
Avg. Volume442,133
Market Cap85.968M
Beta (3Y Monthly)-10.14
PE Ratio (TTM)N/A
EPS (TTM)-0.036
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Cannabics Pharmaceuticals Announces Attendance at the CannMed 2018 Conference, Held at the UCLA Luskin Conference Center, Los Angeles, October 22-24
    PR Newswire7 hours ago

    Cannabics Pharmaceuticals Announces Attendance at the CannMed 2018 Conference, Held at the UCLA Luskin Conference Center, Los Angeles, October 22-24

    TEL AVIV, Israel and BETHESDA, Maryland, Oct. 19, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that Mr. Eyal Barad, Cannabics Pharmaceuticals' Co-Founder and CEO, will be in attendance at the 2018 CannMed conference, held at the UCLA Luskin Conference Center, Los Angeles, between October 22nd – 24th , 2018. CannMed 2018, a Personalized Cannabinoid Medicine Conference, attracts medical cannabis researchers from multiple countries who present their latest findings with regards to the efficacy of treating a variety of conditions with cannabis.

  • PR Newswire3 days ago

    Cannabics Pharmaceuticals Announces Positive Results for Pilot Study on Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)

    Preliminary findings showed more than 80 percent of patients had increase in appetite and 60 percent of patients had over 10 percent weight increase TEL AVIV , Israel and BETHESDA, Maryland, Oct. 16, 2018 ...

  • Join Cannabics Pharmaceuticals at the 3rd CannX Medical Cannabis Conference, Held at Tel-Aviv Convention Center, Israel, October 14-16, 2018
    PR Newswire10 days ago

    Join Cannabics Pharmaceuticals at the 3rd CannX Medical Cannabis Conference, Held at Tel-Aviv Convention Center, Israel, October 14-16, 2018

    TEL AVIV, Israel and BETHESDA, Maryland, Oct. 9, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that members of its management team will be attending the 3rd CannX Medical Cannabis Conference, to be held in the Tel Aviv Convention Centre, on October 14th – 16th  2018, and will be available for one-on-one meetings. The 3rd International Medical Cannabis Conference, CannX, is an annual event for global leaders in areas of Medical Cannabis to convene, explore and present the latest scientific and clinical research in the field. At the convention, Dr. Gil Bar-Sela is scheduled to present his findings of the clinical trial Cannabics completed.

  • PR Newswire25 days ago

    Cannabics Pharmaceuticals Inc. Prices $7,500,000 Registered Direct Offering

    CANNABICS PHARMACEUTICALS INC. (CNBX) ("Cannabics" or the "Company"), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced it has entered into definitive agreements with investors for the purchase and sale of (i) 10,000,000 shares of common stock, par value $0.0001 per share, and (ii) warrants to purchase up to 5,000,000 shares of common stock at a combined offering price of $0.75 per share and warrant, pursuant to a registered direct offering. The warrants will have an exercise price of $1.00 per share, will be immediately exercisable and will expire five years from the date of issuance. The warrants contain customary anti-dilution adjustment provisions and an exercise price protection provision for subsequent issuances below the then current exercise price.

  • Cannabics Pharmaceuticals Inc. Prices $7,500,000 Registered Direct Offering
    PR Newswire25 days ago

    Cannabics Pharmaceuticals Inc. Prices $7,500,000 Registered Direct Offering

    TEL AVIV, Israel and BETHESDA, Maryland, Sept. 24, 2018 /PRNewswire/ -- CANNABICS PHARMACEUTICALS INC. (CNBX) ("Cannabics" or the "Company"), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced it has entered into definitive agreements with investors for the purchase and sale of (i) 10,000,000 shares of common stock, par value $0.0001 per share, and (ii) warrants to purchase up to 5,000,000 shares of common stock at a combined offering price of $0.75 per share and warrant, pursuant to a registered direct offering. The gross proceeds of the offering will be approximately $7,500,000 before deducting placement agent fees and other estimated offering expenses. The Company intends to use the net proceeds for working capital and other general corporate purposes.

  • PR Newswire28 days ago

    Cannabics Pharmaceuticals to Present Results of Clinical Trial at International Medical Cannabis Conference

    TEL AVIV, Israel and BETHESDA, Maryland, Sept. 21, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on Cancer and its side effects, today announced that Dr. Gil Bar-Sela is scheduled to present his findings at the 3rd International Medical Cannabis Conference. This Conference is held for global leaders in areas of Medical Cannabis to convene, explore and present the latest scientific and clinical research in medical cannabis, held in Tel Aviv from October 14th-16th, 2018. Dr. Bar-Sela is the Deputy Director of the Division of Oncology at Rambam Health Care Campus, Head of the Palliative and Supportive Oncology Unit, and Head of the service for Melanoma and Sarcoma patients.

  • ACCESSWIRE29 days ago

    Cannabis and Tech Stocks You Can't Afford to Miss

    HENDERSON, NV / ACCESSWIRE / September 20, 2018 / The Emerging Industries can bring investors gains bigger than one finds in almost any other marketplace. We found a few microcaps that could be the next ...

  • Eroll Grow Tech (Seedo) Merges Its Activities With GRCR Partners; Cannabics Pharmaceuticals to Own 13.6% in the Merged Company
    PR Newswirelast month

    Eroll Grow Tech (Seedo) Merges Its Activities With GRCR Partners; Cannabics Pharmaceuticals to Own 13.6% in the Merged Company

    TEL AVIV, Israel and BETHESDA, Maryland, Sept. 18, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that its partner, Eroll Grow Tech (Seedo), has acquired the majority of shares in GRCR partners, which is publicly traded on the OTC market under the symbol GRCR, as announced yesterday. According to the transaction agreement, Eroll Grow Tech Ltd. (Seedo) will merge its operational activities into GRCR. Cannabics Pharmaceuticals, which provided funds for the transaction, shall eventually receive 13.6% of the merged company, along with a Promissory Note of $350,000 debt owed by Seedo.

  • Cannabics Pharmaceuticals Receives Positive Results in the Development of Cannabinoid-anticancer Drugs
    PR Newswirelast month

    Cannabics Pharmaceuticals Receives Positive Results in the Development of Cannabinoid-anticancer Drugs

    TEL AVIV, Israel and BETHESDA, Maryland, Sept. 14, 2018 /PRNewswire/ --  Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced it has received encouraging results in its preclinical study showing one of its proprietary cannabinoid compounds causing higher rate of cancer cell death compared to traditional chemotherapy (fig.1). Cannabics is rapidly expanding its database of cancer and cannabinoids and established a library of cannabinoid compounds to explore the biological versatility and entourage effect. Recently the company has been granted a patent in Israel on its core technology of screening the effectiveness of cannabis compounds on human biopsies.

  • Cannabics Pharmaceuticals Granted Patent in Israel for Its Core Technology for Personalized Cannabinoid Based Medicine
    PR Newswirelast month

    Cannabics Pharmaceuticals Granted Patent in Israel for Its Core Technology for Personalized Cannabinoid Based Medicine

    TEL AVIV, Israel and BETHESDA, Maryland, Sept. 5, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, has been granted its patent for its core technology by the Israeli Patent Office. This patent encompasses the systems and methods required to produce data on the interaction between different cannabinoids and cancer cells. This technology enables screening the effects of a multitude of compounds derived from the cannabis plant on cancer cell lines and biopsies.

  • PR Newswire2 months ago

    Cannabics Pharmaceuticals Inc. Appoints Dr. Estery Giloz-Ran to Its Advisory Board

    Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, Board of Directors is proud to announce its addition of Dr Giloz-Ran, former manager of Grants Capital Investment, at INTEL Corporation, Israel - to its advisory board. "We are honored to have Dr. Giloz-Ran join our Board of Advisors, her exceptional record in international business management suits us well as our state-of-the-art laboratory comes into operation and we are being approached by potential medical partners to explore joint ventures," said Eyal Ballan, CTO.

  • Cannabics Pharmaceuticals Announces That Seedo is to End Pre-Sales and Commence Delivery of Its Automated Growing Devices
    PR Newswire2 months ago

    Cannabics Pharmaceuticals Announces That Seedo is to End Pre-Sales and Commence Delivery of Its Automated Growing Devices

    Aug. 22, 2018, TEL AVIV, Israel and BETHESDA, Maryland /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that Eroll Grow Tech Ltd ("Seedo"), developer of the world's first fully-automated grow device designed specifically for medical cannabis, is to end Seedo's pre-sale on September 12th at midnight EST, and commence scheduled delivery of its first units to customers in the coming weeks. Recently CNBX partnered with Seedo to help bring forth the company's immediate vision of supplying personalized growing units into the market, and to cooperate on enabling consistent, pesticide free, pharmaceutical-grade cannabis worldwide on a commercial scale.

  • Cannabics Pharmaceuticals Partners with Eroll Grow Tech to Create First Auto-Grow Device for Medical Cannabis
    PR Newswire2 months ago

    Cannabics Pharmaceuticals Partners with Eroll Grow Tech to Create First Auto-Grow Device for Medical Cannabis

    TEL AVIV, Israel and BETHESDA, Maryland, Aug. 14, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced a partnership agreement with Eroll Grow Tech ltd ("Seedo"), developer of the world's first fully-automated grow device designed specifically for cannabis. Through this new partnership, Cannabics and Seedo will develop the first controlled device for growing medical cannabis at home, ensuring sustainable quality and supply of natural, pesticide free product. The fully-automated grow device will be managed and controlled by an artificial intelligence algorithm and monitored by a smart phone app, using technology successfully implemented by Seedo for recreational growth.

  • PR Newswire2 months ago

    Cannabics Pharmaceuticals Announces Attendance at the Benzinga Cannabis Capital Conference

    TEL AVIV, Israel and BETHESDA, Maryland, Aug. 10, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that its CEO, Mr. Eyal Barad, will be attending the Benzinga Cannabis Capital Conference, to be held at the Toronto Arcadian Centre, on August 16th-17th 2018, and will be available for one on one meetings. The Cannabis Capital Conference is presented by Benzinga, a leading financial media outlet with extensive coverage of the cannabis space. Benzinga is a financial media outlet that empowers investors with unique content that is recognized by Wall Street traders.

  • PR Newswire2 months ago

    Join Cannabics Pharmaceuticals at the MJBizCon Held at Metro Toronto Convention Center, Toronto, August 14-16, 2018

    TEL AVIV, Israel and BETHESDA, Maryland, August 9, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that its CEO, Mr. Eyal Barad, will be attending the MJBizCon Conference and Expo, to be held in the Toronto Metro Convention Centre, on August 14th-16th  2018, and will be available for one-on-one meetings. Eyal Barad, CEO of the company, said: "We are excited to be able to meet and network with fellow companies in the Cannabis sector. Cannabics Pharmaceuticals Inc. (CNBX) is a United States-based public company that is developing cannabinoid diagnostic tests for the personalized treatment of cancer.

  • PR Newswire3 months ago

    Cannabics Pharmaceuticals' CEO Issues Letter to Shareholders

    Now that we have officially moved into our new state-of-the-art Cancer Screening Laboratory located in Rehovot, Israel we are poised for symbiotic scientific partnerships. Both the company and our new Laboratory are broadly licensed by the Ministry of Health in Israel specifically for R&D on Cannabis.  We see great potential in scientific collaborations with like-minded companies that are engaged in cannabinoid medicines and diagnostics. As such we are waiting for numerous approvals from various national level registrations on our Cannabinoid – Cancer screening patents.

  • PR Newswire3 months ago

    Join Cannabics Pharmaceuticals at the National Cannabis Industry Association's Cannabis Business Summit and Expo Held at San Jose Convention Center, California USA, July 25-27, 2018

    TEL AVIV, Israel and BETHESDA, Maryland, July 11, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that senior members of its team will be attending the National Cannabis Industry Association Business Conference and Expo, to be held in San Jose convention center, California, USA, on July 25th-27th 2018, and will be available for one on one meetings. The National Cannabis Industry Association, or NCIA, is the industry's premier organization in the United States, and the Business conference and expo held in San Jose is their 5th and largest event to date. In attendance will be Mr. Eyal Barad, Co-Founder and CEO, alongside Mr. Noam Permont, VP of Business Development.

  • PR Newswire4 months ago

    Cannabics Pharmaceuticals Announces Conclusion of Clinical Trial on Cannabics SR 5mg for Cancer Anorexia Cachexia Syndrome (CACS)

    TEL AVIV, Israel and BETHESDA, Maryland, July 3, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), leader in personalized cannabis medicine focused on cancer and its side effects, announced today that it has concluded its clinical trial held at Rambam Medical Center.  The Oncology Center at Rambam Medical Center is recognized by the European Society for Medical Oncology (ESMO) as a designated Center of Integrated Oncology and Palliative Care.

  • Cannabics Pharmaceuticals Enters a Memorandum of Understanding With Clinical-Stage Biopharmaceutical Company Focused on the Treatment of Ophthalmic Disorders
    PR Newswire4 months ago

    Cannabics Pharmaceuticals Enters a Memorandum of Understanding With Clinical-Stage Biopharmaceutical Company Focused on the Treatment of Ophthalmic Disorders

    TEL AVIV, Israel and BETHESDA, Maryland, June 29, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabis medicine focused on cancer and its side effects, announced today that it has entered a memorandum of understanding with a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, and that has distribution rights of known medical formulae related to eye diseases. The new entity will focus on exploring the potential of alleviating the effects of eye disorders and infections using cannabinoids, while reducing use of steroid based products which are currently widely used.

  • PR Newswire4 months ago

    Cannabics Pharmaceuticals to Participate in the International Cannabis Research Society Annual Forum in Leiden, the Netherlands

    TEL AVIV, Israel and BETHESDA, Maryland, June 26, 2018 /PRNewswire/ --  Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabis medicine focused on cancer and its side effects, announced today that senior members of its scientific team will be attending the International Cannabinoid Research Society conference, to be held in Leiden, the Netherlands July 1st – 4th 2018, and will be available for one on one meetings. The International Cannabinoid Research Society, ICRS, a non-political organization, is dedicated to scientific research in all fields of cannabinoids, ranging from biochemical, chemical and physiological studies of the endogenous cannabinoid system.

  • FSD Pharma Appoints Dr. Zohar Koren as Head of Scientific Advisory Board
    CNW Group4 months ago

    FSD Pharma Appoints Dr. Zohar Koren as Head of Scientific Advisory Board

    FSD Pharma Appoints Dr. Zohar Koren as Head of Scientific Advisory Board

  • PR Newswire5 months ago

    Join Cannabics Pharmaceuticals at LCBC Cannabis Professional Conference Held at MTCC, Toronto, Canada, May 25-27, 2018

    TEL AVIV, Israel and BETHESDA, Maryland , May 24, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals (OTCQB: CNBX), a US bio-pharma company developing novel cannabis-based, personalized medicine solutions ...

  • Cannabics Pharmaceuticals Hires Two New Scientists to Further Develop Cannabinoid Diagnostic Tests and Treatments for Cancer
    PR Newswire5 months ago

    Cannabics Pharmaceuticals Hires Two New Scientists to Further Develop Cannabinoid Diagnostic Tests and Treatments for Cancer

    TEL AVIV, Israel and BETHESDA, Maryland, May 22, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), leader in cannabinoid diagnostic tests for personalized cancer treatment, announced today the appointment of Haleli Sharir, Ph.D. as principal scientist and Nir Kfir, Ph.D. as senior scientist. The two new team members will support Cannabics' data-discovery process with the goal of identifying new cannabinoid diagnostic tests and treatments for cancer.

  • PR Newswire6 months ago

    Cannabics Pharmaceuticals Announces Collaboration With Life Source Partners CEO Muriel Zohar to Optimize Technology Applications and Evaluate New Opportunities

    Dr. Zohar will support strategic business planning as Cannabics enters $10 million Standby Equity Distribution Agreement with YAII PN, Ltd. Cannabics Pharmaceuticals Inc. (CNBX), leader in cannabinoid diagnostic tests for personalized cancer treatment, today announced that CEO of Life Source Partners Ltd., Muriel Zohar, Ph.D, MBA, will be working with Cannabics to advance personalized and palliative cannabinoid cancer care.

  • PR Newswire7 months ago

    Cannabics Pharmaceuticals Receives Positive Results From Preclinical Study on Antitumor Effects of Cannabinoids

    Cannabics Pharmaceuticals Inc. (CNBX), a leader in cannabinoid diagnostic tests for personalized cancer therapy, today announced encouraging results from a preclinical study on the antitumor effects of cannabinoids on cancerous tumor cells. The study indicates that cancer cells derived from patient blood samples are differentially sensitive to the main active compounds in cannabis, tetrahydrocannabinol (THC) and tetrahydrocannabinolic acid (THCA).